

## A Personalized Risk Score for Coronary Artery Disease

MyOme's Integrated Polygenic Risk Score™ (iPRS™) Coronary Artery Disease (CAD) test combines whole-genome with clinical risk assessment, delivering a more accurate risk prediction to guide healthcare decisions.



### Better Risk Prediction can Tailor Management to Improve Health Outcomes

#### Comprehensive Analysis

Approximately

**50%**

of CAD risk is due to heritable factors, many of which can be detected as genetic markers by the iPRS test.<sup>1</sup>

#### Reliable Risk Stratification

Nearly

**10%**

of patients with uncertain\* 10-year risk of CAD (as determined by traditional methods) were reclassified as high-risk by iPRS.<sup>2</sup>

#### Hidden Risk Detection

Cases reclassified by iPRS had


**3X**

higher 10-year risk of CAD incidence, underscoring the value of accurate risk stratification.<sup>2</sup>

### iPRS for Coronary Artery Disease

#### Patients can receive an iPRS result if they:

- Are aged 40-79
- Do not have a personal history of CAD
- Have all clinical measurements required to calculate risk



\*Uncertain risk is defined as having borderline or intermediate risk scores

\*\*Atherosclerotic Cardiovascular Disease

**Key Features**

**Multi-Ancestry Applicability**



Data from >150K patients in four large international cohorts was used to validate iPRS, enabling cross-ancestry risk prediction<sup>2</sup>

**Actionable Recommendations**



Results include recommendations for a heart-healthy lifestyle and may recommend that providers start patients on medication

**Genetic Counseling**



Optional support from a trained genetic counselor is available to help ensure comprehensive risk assessment and management

**Important Considerations:** The iPRS CAD test is intended as a risk assessment tool, NOT a diagnostic. Some people with a high risk score will not develop CAD and some with a low risk score will develop CAD.

**A Simple, Seamless Process**

Ordering	Sample Collection	Sample Analysis	Receiving Results
Submit a request via MyOme's secure portal	Use instructions provided in blood, saliva, or buccal swab collection kits	Return sample to MyOme for sequencing and data analysis	Reports with risk assessment results and relevant actionable insights are delivered through a secure portal



**Support at Every Step**

We are committed to helping providers communicate complex topics by providing videos, materials, and other resources to support patient education.



**Get started with MyOme today.**  
 Contact [support@myome.com](mailto:support@myome.com) to set up an account.

This test was developed, and its performance characteristics were determined, by MyOme, Inc., a clinical laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and College of American Pathologist (CAP) accredited to perform high complexity clinical laboratory testing. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Test results should always be interpreted by a clinician in the context of clinical and familial data with the availability of genetic counseling when appropriate. MyOme is not responsible for the content or accuracy of third-party websites.

1. McPherson R and Tybjaerg-Hansen A. Genetics of CAD. Circulation Research. 19 Feb 2016; 118 (4). doi: 10.1161/CIRCRESAHA.115.306566 2. Ratman D, Tshiaba P, Levin M, et al. PRS Improves 10-year Risk Prediction of Coronary Artery Disease in Individuals at Uncertain Clinical Risk. JAMA (in revision). 2024. 3. Medina-Inojosa J, Somers V, Garcia M, et al. Performance of the ACC/AHA Pooled Cohort Equations in Clinical Practice. J Am Coll Cardiol. 2023 Oct 10; 82(15):1499-1508. doi: 10.1016/j.jacc.2023.07.018.